Innovative chemo-genomic tools to improve clinical outcome in acute myeloid leukemia

More accurate prognostic test for better management of patients with acute myeloid leukemia

Acute myeloid leukemia is a particularly lethal form of cancer, with most patients dying within two years of diagnosis. It is one of the leading causes of death among young adults. Existing prognostic tests are often inaccurate, leaving doctors with no tools to guide their decision making about treatment options. 

The project will help increase the survival rate of patients with acute myeloid leukemia by helping to determine treatment based on the genetic makeup of their leukemia cells. By giving hemato-oncologists access to more accurate tools, this project will help pave the way for a new era in personalized medicine and offer patients better targeted therapies. It can also help avoid unnecessary hospitalizations and treatments, while generating significant savings in health care expenditures – a potential sum of $34 million annually.

Co-applicants and End-users: